RET and neoplasm: MD Anderson Group demonstrated that circulating RET M918T cell-free DNA (cfDNA) could be detected in about 1/3 of sporadic MTC patients with elevated serum Ct level (>100 pg/mL) and advanced disease stages, harboring RET M918T mutation in tumor cells.